Effects of paclitaxel combined with loplatin on serum SCCA,serum tumor-related substance(TAM)and vascular endothelial growth factor levels in patients with cervical cancer
Objective:Objective To investigate the effects of paclitaxel combined with loplatin on serum Squamous cell carcinoma antigen(SCCA)and serum Tumor associated material(Tumor associated material)in patients with cervical cancer.TAM and Vascular endothelial growth factor(VEGF)levels were associated with endothelial growth factor.Methods:A total of 82 patients with cervical cancer who received chemotherapy in our hospital from October 2020 to October 2022 were selected as research objects and divided into control group and observation group by random number table method,with 41 cases in each group.The control group received nedaplatin combined with paclitaxel preoperative neoadjuvant chemotherapy,the observation group received loplatin combined with paclitaxel preoperative neoadjuvant chemotherapy.The therapeutic effects,serum SCCA,TAM,VEGF levels,adverse drug reactions and patient satisfaction of the two groups were analyzed and compared.Results:The total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,the serum levels of SCCA,TAM and VEGF in both groups were significantly decreased,and the serum levels of SCCA,TAM and VEGF in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total satisfaction of the observation group was significantly higher than that of the control group(P<0.05).Conclusion:Loplatin combined with paclitaxel can effectively improve the levels of serum SCCA,TAM and VEGF in the treatment of cervical cancer,and the drug side effects are mild.
NETL
NSTL
万方数据
维普
